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AMP-activated protein kinase (AMPK) plays a central
role in regulating metabolism and energy homeosta-
sis. It achieves its function by sensing fluctuations
in the AMP:ATP ratio. AMP deaminase (AMPD) con-
verts AMP into IMP, and the AMPD1 isoenzyme is
expressed in skeletal muscles. Here, effects of phar-
macological inhibition and genetic deletion of AMPD
were examined in contracting skeletal muscles. Phar-
macological AMPD inhibition potentiated rises in
AMP, AMP:ATP ratio, AMPK Thr172, and acetyl-CoA
carboxylase (ACC) Ser218 phosphorylation induced
by electrical stimulation, without affecting glucose
transport. In incubated extensor digitorum longus
and soleus muscles from Ampd1 knockout mice, in-
creases inAMP levels andAMP:ATP ratio by electrical
stimulation were potentiated considerably compared
withmuscles fromwild-typemice, whereas enhanced
AMPK activation was moderate and only observed
in soleus, suggesting control by factors other than
changes in adenine nucleotides. AMPD inhibitors
could be useful tools for enhancing AMPK activation
in cells and tissues during ATP-depletion.
INTRODUCTION
AMP-activated protein kinase (AMPK) is a highly conserved eu-
karyotic energy sensing serine/threonine protein kinase (Kahn
et al., 2005; Steinberg and Kemp, 2009; Witters et al., 2006).
The AMPK heterotrimer contains a catalytic a subunit and two
regulatory subunits, b and g, of which there are multiple isoforms
giving at least 12 possible combinations of holoenzyme with
different tissue distribution and subcellular localization. AMPK
can be activated by changes in intracellular AMP:ATP ratio, as
occurs, for example, as a result of anoxia or other metabolic
stresses, or via an increase in intracellular Ca2+. LKB1 (the
Peutz-Jeghers protein) and Ca2+/calmodulin-dependent protein
kinase kinase-b are upstream kinases that activate AMPK byChemistry & Biology 21, 1497–151phosphorylating Thr172 in the activation loop of the catalytic a
subunits, essential for AMPK activation. Once activated, AMPK
phosphorylates metabolic targets, resulting in a decrease in
ATP consumption and stimulation of ATP production. An impor-
tant role of AMPK activation in skeletal muscle is to stimulate
glucose transport, which partly accounts for the beneficial ef-
fects of exercise for the management of type 2 diabetes (Liu
et al., 2013; Richter and Ruderman, 2009).
Using semipurified native and purified recombinant AMPK
preparations, the mechanism by which a rise in AMP leads to
AMPKactivation has been proposed to involve: (1) allosteric stim-
ulation of the phosphorylated enzyme; (2) promotion of Thr172
phosphorylation by upstreamkinase; and (3) inhibition of dephos-
phorylation of Thr172 by protein phosphatases (Davies et al.,
1995; Oakhill et al., 2011; Sanders et al., 2007; Xiao et al., 2011).
The crystal structureof the core heterotrimer indicated four nucle-
otide binding sites on the AMPK g subunits, one empty, one con-
taining nonexchangeable AMP, and two sites which reversibly
bind AMP (Oakhill et al., 2011; Xiao et al., 2007, 2011). AMP bind-
ing toahigheraffinitysite is responsible for allosteric stimulationof
AMPK, whereas AMP binding to the lower affinity site protects
against dephosphorylation. ADP can bind to the low and high af-
finity sites and also prevents Thr172 dephosphorylation, but does
not allosterically stimulate AMPK. Because free ADP concentra-
tions are usually much higher than those of free AMP in energy
stressed cells, and because their binding constants are similar,
it was argued that ADP would be more physiologically important
for AMPK activation (Xiao et al., 2011). AMPK has been proposed
to be an energy charge-regulated protein kinase on the basis that
increases in both ADP/ATP, as well as AMP/ATP, stimulated
Thr172 phosphorylation by upstream kinase in vitro (Oakhill
et al., 2011). However, a recent reinvestigation using native
AMPK purified from rat liver indicates that AMP is an important
physiological regulator of overall activation (Gowans et al., 2013).
The intracellular concentration of AMP depends on the ac-
tivities of adenylate kinase, AMP deaminase (AMPD), cytosolic
50-nucleotidases (cN-IA and cN-II), adenosine kinase, and other
salvage pathway enzymes. AMPD1 is highly expressed in
skeletal muscle, AMPD2 is predominant in nonmuscle tissues,
and AMPD3 is found in erythrocytes (Mahnke-Zizelman et al.,
1998; Morisaki et al., 1990; Ogasawara et al., 1978). However,
AMPD expression is complex and can result in a variety of0, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1497
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man et al., 1998; Ogasawara et al., 1982, 1984). The nucleotidase
cN-IA is specific for AMP and expressed in muscle and heart,
whereas cN-II preferentially hydrolyses inosine monophosphate
(IMP) and is ubiquitous (Bianchi and Spychala, 2003). Because
of their high catalytic efficiency in spite of their low apparent affin-
ity for AMP, AMP-metabolizing enzymes could influence intracel-
lular AMP concentrations. Thus, inhibiting AMP-metabolizing
enzymes might be a strategy for achieving AMPK activation in
cells. An analogy can be made with PDE-5 cyclic nucleotide
phosphodiesterase inhibitors, such as Viagra and related com-
pounds, usedclinically toactivate cyclicGMP-dependent protein
kinase for the treatment of erectile dysfunction and pulmonary
hypertension (Francis et al., 2011). While AMPD seemed to
have little control over intracellular AMP concentrations in human
embryonic kidney 293 cells stimulated by oligomycin (Plaideau
et al., 2012), gene silencing of cN-II in human muscle and cN-IA
in mouse muscle increased the intracellular AMP/ATP ratio, in-
creased AMPK Thr172 phosphorylation, and increased AMPK
downstream signaling (Kulkarni et al., 2011).
The interest in AMPK by pharmaceutical companies as a drug
target for the treatment of type 2 diabetes stems from the finding
that AMPK activation in muscle during exercise stimulates
glucose uptake, independent of insulin, and the fact that the anti-
diabetic drug metformin, prescribed world-wide to some 120
million people, activates AMPK (Jalving et al., 2010; Mantovani
and Roy, 2011; Viollet et al., 2006). However, metformin action
seems to be principally due to reduction in glucose output by
the liver. Direct AMPK activation is complicated by the existence
of at least 12 different heterotrimeric complexes. A769662, a thie-
nopyridone compound, only seems to activate AMPK complexes
containing the b1 subunit (Scott et al., 2008), which is poorly ex-
pressed in human liver and skeletal muscle where AMPK activa-
tion would be most beneficial for counteracting the symptoms of
type 2 diabetes (Hunter et al., 2011; Lai et al., 2010; Saha et al.,
2010). Therefore, because glucose is mainly disposed of in hu-
mans by uptake into muscle, and because AMPD activity is high-
est in this tissue (Moriwaki et al., 1999), we focused on the effects
of AMPD1 inhibition as an alternative means of achieving AMPK
activation. In the paper accompanying this article, we character-
ized two reversible AMPD inhibitors, compound 3 and compound
4, and studied their effects onmetabolism both in vitro and in vivo
(see Admyre et al., 2014 in this issue of Chemistry & Biology). In
skeletal muscle, AMPD has a much higher activity than in other
tissues (Moriwaki et al., 1999). Therefore, we tested the effects
of compounds 3 and 4 on AMPK activation during contraction
in incubated rat skeletal muscles. We also investigated AMPK
activation by contraction in incubated muscles from whole-
body Ampd1 knockout mice.
RESULTS
Measurements of Total Purine Nucleotides and
AMP-Activated Protein Kinase Activation in Rat
Epitrochlearis Muscles Subjected to Increasing
Frequencies of Electrical Stimulation
Incubated rat epitrochlearis muscles were subjected to three fre-
quencies of electrical stimulation (0.2 Hz; 200 ms/5 s, 0.5 Hz;
200 ms/2 s, and 1 Hz; 200 ms/1 s) for 10 min to obtain a graded1498 Chemistry & Biology 21, 1497–1510, November 20, 2014 ª2014increase in contraction. The muscles were then frozen in liquid
N2 and extracted in HClO4/CH3OH for total nucleotide measure-
ments by high-performance liquid chromatography (HPLC). In
parallel, muscles were incubated using the same protocol, and
extracts were prepared for immunoprecipitation/AMPK assay
and immunoblotting. Muscle contraction depleted ATP by about
45% and increased total ADP concentrations by about 30%
compared with the resting condition. However, the changes
in ATP and ADP did not vary with the intensity of contraction
(Table 1). Importantly, low-frequency electrical stimulation in-
creased AMP concentrations 8-fold compared with resting con-
trols, but AMP levels then slightly decreased as the intensity of
contraction increased (Table 1). Moreover, IMP levels rose
60-fold at low intensities of contraction compared with resting
muscles and further increased as the frequency of electrical
stimulation increased. In our previous studies, the KM of recom-
binant AMPD1was 3.4mM,which decreased to about 0.2mM in
the presence of ligands at their physiological concentrations
(Plaideau et al., 2012). Therefore, the levels of IMP reached at
the highest frequency of electrical stimulation (2.8 mmol/g) might
cause product inhibition of AMPD1. In any case, our data are
indicative of flux through AMPD, increasing with the intensity of
contraction. This is in agreement with an old observation that
ammonia is produced by contracting muscle, also indicative of
flux through AMPD (Lowenstein and Tornheim, 1971). Adenosine
content increased about 5-fold, but levels did not vary with the
frequency of electrical stimulation (Table 1). Contraction also
increased the AMP/ATP and ADP/ATP ratios and decreased
the adenylate energy charge (AEC) as defined by Atkinson
(1968). However, the AMP/ATP, ADP/ATP ratios, and AEC did
not change significantly as the intensity of contraction increased,
and there was some loss of total adenine nucleotides (Table 1).
AMPK activity increased 5-fold at the lowest frequency (0.2 Hz)
of electrical stimulation and further increased 7-fold at 0.5 Hz
electrical stimulation, decreasing slightly with 1 Hz of stimulation
(Table 1). AMPK Thr172 and acetyl-CoA carboxylase (ACC)
Ser218 phosphorylation were increased by contraction, but did
not significantly change with increasing frequencies of electrical
stimulation (data not shown).
Pharmacological AMP Deaminase Inhibition in Rat
Epitrochlearis Muscles Potentiated AMP-Activated
Protein Kinase Activation by Contraction But Did Not
Affect Contraction-Stimulated Glucose Uptake
We have developed, characterized, and studied two AMP-
competitive AMPD inhibitors, compounds 3 and 4, in the accom-
panying paper (see Admyre et al., 2014 in this issue of Chemistry
& Biology). These inhibitors were tested in our muscle contraction
model. Preincubation of muscles with 27 mM compound 3 (final
effective, unbound concentration 20 mM taking into account
binding to albumin) prior to 10 min of electrical stimulation
(200ms trains delivered every 5 s, corresponding to the lowest in-
tensity of contraction in Table 1) did not alter contraction-medi-
ated changes in total ATP and ADP concentrations (Figures 1A
and 1B). However, treatment with compound 3 greatly enhanced
the rise in AMP induced by low-frequency electrical stimulation
(Figure 1C). Preincubation with compound 3 decreased basal
IMP levels, but did not significantly affect the contraction-induced
increases in IMP, adenosine, and inosine (Figures 1D–1F).Elsevier Ltd All rights reserved
Table 1. Changes in AMP-Activated Protein Kinase Activity and Purine Nucleotide Concentrations in Rat Epithroclearis Muscles
Subjected to Graded Increases in Electrical Stimulation
Rest 200 ms/5 s1 200 ms/2 s1 200 ms/1 s1
AMPK activity 3.5 ± 0.7 19.0 ± 2.2a 24.3 ± 0.6a,b 15.6 ± 1.7a,c
AMP 7.8 ± 1.3 65.1 ± 21.1a 55.0 ± 20.4a 46.0 ± 17.1a
ADP 601 ± 22 823 ± 53a 727 ± 27a 837 ± 54a
ATP 4,452 ± 118 2,768 ± 191a 2,154 ± 160a 2,570 ± 336a
AMP/ATP (%) 0.17 ± 0.02 2.47 ± 1.09a 2.70 ± 1.14a 1.98 ± 0.93a
ADP/ATP (%) 13.5 ± 0.7 30.0 ± 2.8a 34.0 ± 1.7a 33.4 ± 3.3a
AEC 0.94 ± 0.01 0.87 ± 0.01a 0.86 ± 0.01a 0.86 ± 0.01a
Total adenine nucleotides 5,061 ± 117 3,657 ± 193a 2,936 ± 170a 3,453 ± 370a
Adenosine 2.4 ± 0.3 13.8 ± 4.7a 12.5 ± 2.1a 10.7 ± 1.6a
IMP 26 ± 9 1,575 ± 375a 2,363 ± 199a 2,972 ± 472a,b
Inosine 6.3 ± 3.6 47.6 ± 9.9a 74.3 ± 8.1a,b 68.5 ± 7.6a
Hypoxanthine 0.9 ± 0.4 11.9 ± 2.8a 12.6 ± 1.8a 14.6 ± 1.9a
Incubated epithroclearis muscles were untreated or electrically stimulated with 200 ms trains of square-waves pulses delivered every 5, 2, and 1 s
(200ms/5 s1, 200ms/2 s1, and 200ms/1 s1). Homogenates were prepared for AMPK assay. AMPK activity is expressed in mUnits.mg of protein1.
Total intracellular nucleotide and nucleoside concentrations (nmol.g of wet weight1) were determined in perchloric acid extracts by HPLC. AEC and
total adenine nucleotides were calculated (see legend to Figure 1). Results are means ± SEM, n = 4 for AMPK activity, and n = 34 for nucleotide con-
centrations.
ap < 0.05 versus resting.
bp < 0.05 versus 200 ms/5 s.
cp < 0.05 versus 200 ms/2 s.
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Inhibition of AMPD and Effects on AMPK ActivationTreatment with compound 3 potentiated the effects of contrac-
tion to increase the AMP/ATP ratio and decrease the AECwithout
affecting the rise in ADP/ATP ratio (Figures 1G–1I). Importantly,
the enhanced increase in AMP levels by compound 3 seen during
contraction was reflected by the potentiation of increased AMPK
Thr172 and ACC Ser218 phosphorylation in electrically stimu-
lated muscles (Figures 1J–1L).
As reported in the adjoining paper (see Admyre et al., 2014
in this issue of Chemistry & Biology), compound 4 is a more
potent AMPD inhibitor than compound 3. Preincubation of mus-
cles with 27 mM compound 4 had similar effects on contraction-
induced changes in purine nucleotide concentrations, ADP/ATP
and AMP/ATP ratios, AEC, and AMPK/ACC phosphorylation to
those observed with compound 3 (Figure 2). However, preincu-
bation with compound 4 induced higher levels of AMP (up to
300 nmol/g wet weight) in response to contraction (Figure 2C).
Also by contrast with compound 3, preincubation with com-
pound 4 led to a more substantial drop in IMP during electrical
stimulation (Figure 2D). In addition, the contraction-induced in-
creases in adenosine and inosine were elevated by treatment
with compound 4 (Figures 2E and 2F). In spite of the fact that
treatment with 27mM compound 4 also significantly enhanced
the increase in ACC phosphorylation and tended to enhance
the increase in AMPK phosphorylation (p = 0.08) during
contraction (Figures 2J–2L), neither compound 4 nor compound
3 treatment increased contraction-stimulated glucose uptake
(Figure S1 available online).
Contraction-InducedChanges in AMP-Activated Protein
Kinase Activity and Purine Nucleotide Levels in Muscles
from Wild-Type and Ampd1 Knockout Mice
Mice bearing a whole body deletion of Ampd1were generated to
further study whether the absence of AMPD1 in skeletal musclesChemistry & Biology 21, 1497–151would potentiate AMPK activation, as seen with AMPD inhibi-
tors. Interestingly, mRNA profiling in humans suggests that
AMPD1 expression is exclusive to skeletal muscle with little or
no expression in heart and smooth muscles (Bio GPS, see http://
biogps.org/#goto=genereport&id=270). The Ampd1 knockout
(KO) mice were healthy and appeared normal displaying no
obvious phenotype (see Admyre et al., 2014 in this issue of
Chemistry & Biology).
AMPD activity was decreased by 90% in extracts from
extensor digitorum longus (EDL) and by 70% in extracts from
soleus muscles of Ampd1 KO mice compared with wild-type
mice (Figures 3A and 3C). Since AMPD1 binds to the skeletal
muscle contractile apparatus and because extracts were pre-
pared in low salt, the enzyme activities presented in Figure 3
may not represent the total skeletal muscle activities. Using a
commercial anti-AMPD1 antibody, immunoblot analysis re-
vealed the presence of major bands in EDL and soleus from
wild-type mice (Figure 3E), which comigrated with a major
90,000-relativemolecular mass (Mr) band seenwith recombinant
human AMPD1 (data not shown), but the bands were unde-
tectable in EDL and soleus muscles from Ampd1 KO mice
(Figure 3E). Although fainter 50,000-Mr bands were seen in im-
munoblots of both EDL and soleus from wild-type mice, these
bands were also present in the same blots for EDL and soleus
from Ampd1 KO mice (data not shown). AMPD2 could be de-
tected in EDL by immunoblotting, and AMPD2 signals were
higher in soleus than in EDL muscles (Figure 3E). However, there
is no evidence to indicate that the AMPD2 gene is expressed in
skeletal muscle (Bausch-Jurken et al., 1992), and AMPD2 de-
tected by immunoblotting might have been due to nonmyocyte
elements in the tissue (van Kuppevelt et al., 1994). AMPD3
expression was only detectable in soleus muscle, as reported
previously (Wang et al., 1997). Importantly, there was no0, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1499
(legend on next page)
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Inhibition of AMPD and Effects on AMPK Activationincrease in AMPD2 or AMPD3 expression in muscles from
Ampd1 KO versus wild-type mice.
AMPK activity increased significantly by 2-fold in both EDL
and soleus from wild-type mice after 5 min of electrical stimula-
tion compared with the resting condition (Figures 3B and 3D).
AMPK activation by contraction in EDL deleted for Ampd1 was
similar to that observed inmuscles fromwild-typemice, whereas
in soleus from Ampd1 KO mice, AMPK activation was potenti-
ated from 2- to 3-fold. That a more pronounced effect of de-
leting Ampd1 on contraction-induced AMPK activation was not
seen is very surprising, in view of the dramatic changes in nucle-
otide and nucleoside concentrations seen compared with wild-
type mice (EDL, Figure 4; soleus, Figure 5; discussed below).
This was not due to differences in activation of a1- versus a2-
containing AMPK complexes. Similar degrees of AMPK activa-
tion by contraction were seen following immunoprecipitation of
extracts fromwild-type versus Ampd1 KO EDL, and soleusmus-
cles with anti-a1 and anti-a2 AMPK catalytic subunit antibodies
(data not shown) compared to effects observed when total (a1 +
a2) AMPK activity was measured (Figure 3).
In EDLmuscles from both wild-type andAmpd1KOmice, ATP
levels were depleted to a similar extent by contraction (Fig-
ure 4A). However, the AEC decreased more in response to elec-
trical stimulation in EDL from Ampd1 KO mice compared with
wild-type mice (Figure 4J). Impressively, while the increases in
AMP and ADP concentrations induced by contraction in EDL
from wild-type mice were only 60% and 7% compared with
the resting condition, respectively, there was a large 7-fold in-
crease in AMP and 2.5-fold increase in ADP in response to
5 min of electrical stimulation of EDL muscles from Ampd1 KO
mice (Figures 4B and 4C). In parallel, the AMP:ATP and ADP:ATP
ratios were increased10- and3-fold in electrically stimulated
EDL from Ampd1 KO mice compared to the resting condition,
whereas the increases were only 2-fold and 1.5-fold in mus-
cles, respectively, from wild-type mice (Figures 4D and 4E). IMP
concentrations were clearly increased by electrical stimulation of
EDL from wild-type mice, however levels were severely abro-
gated in both resting and contracted EDL from Ampd1 KO
mice (Figure 4F). Electrically stimulated EDL muscles from
Ampd1 KO mice tended to produce more adenosine than EDL
from wild-type mice (Figure 4G), possibly due to rerouting of
AMP through cN-1A due to the lack of AMPD1. The loss of ino-
sine and hypoxanthine by contraction was less in EDL from
Ampd1 KO mice compared with wild-type mice (Figures 4H
and 4I), and Ampd1 deficiency seemed to protect against the
drop in the total adenine nucleotide pool following contraction
(Figure 4K).Figure 1. Effect of Compound 3 on Purine Nucleotide Concentration
Epitrochlearis Muscle
Isolated rat epitrochlearis muscles were preincubatedwith 0.1% (v/v) DMSO as ve
stimulation (200 ms trains delivered every 5 s, black bars) or incubated for 10 mi
(A)–(F) Total purine nucleotide concentrations were measured in perchlorate extr
weight1, n = 4.
(G and H) ADP/ATP, AMP/ATP ratios, (I), AEC (ATP + 1/2ADP)/(ATP + ADP + AM
(K and L) Separate gels with equal protein loading were made for blot quantificatio
with the anti-phospho antibodies relative to that of the anti-total ACC or AMPK a
(M) Representative immunoblots show signals obtained with phospho-ACC, tota
Values are means and error bars represent SEM. *Indicates a significant differen
Chemistry & Biology 21, 1497–151Overall the effects of electrical stimulation on nucleotide levels,
AMP:ATP, ADP:ATP ratios, and AEC in soleusmuscles fromwild-
type versus Ampd1 KO mice (Figure 5) were similar to those
observed in EDL (Figure 4). However, the AEC was decreased
more in response to contraction in soleus from both wild-type
and Ampd1 KO mice (Figure 5J) than seen in EDL (Figure 4J).
Interestingly, ADP concentrations in soleus from wild-type and
Ampd1 KO mice were not increased by contraction, although
ADP levels were higher in muscles from Ampd1 KO mice com-
pared with wild-type mice (Figure 5B). AMP was also more
elevated in soleus from Ampd1 KO mice (Figure 5C) and upon
contraction increased to higher levels than seen in EDL from
Ampd1 KO mice (Figure 4C), although the fold-increase in AMP
induced by contraction in soleus (Figure 5C) was somewhat less
than in EDL from Ampd1 KOmice (Figure 4C). Unlike in EDLmus-
cles, IMP concentrations were not significantly reduced in soleus
from Ampd1 KO compared with wild-type mice, however the rise
in IMP induced by contraction in soleus from wild-type mice was
clearly abrogated in mice deficient in AMPD1 (Figure 5F), as was
the case for inosine (Figure 5H). The fact that some of the effects
of contraction in soleuswere not as clear cut as seen inmice lack-
ing AMPD1 in EDLmight have been due to residual AMPD activity
in soleus from Ampd1 KOmice (Figure 3C), probably contributed
by AMPD2 and AMPD3. Also, differences between fast-twitch
EDL and slow-twitch soleus isolated from Ampd1 KOmice could
be related to their different fiber composition.
In both EDL and soleusmuscles, glycogen content and lactate
concentrations were not significantly different between wild-
type and Ampd1 KO mice (Tables S1 and S2). Moreover, the ef-
fects of electrical stimulation to decrease glycogen content and
increase lactate concentrations were not different in EDL and so-
leus muscles from wild-type versus Ampd1 KO mice (Tables S1
and S2). In EDL, phosphocreatine (PCr) concentrations at rest
were similar in wild-type compared with Ampd1 KO mice, and
the effect of contraction to decrease PCr levels was similar (Ta-
ble S1). However, PCr concentrations were significantly lower in
soleus muscles from Ampd1 KO versus wild-type mice, and the
effect of electrical stimulation to decrease PCr content wasmore
pronounced in soleus from wild-type mice (Table S2). The
decrease in PCr content in soleus from Ampd1 KO versus
wild-type mice in the resting condition might be related to
increased basal ADP concentrations (Figure 5B), which were
not seen in EDL (Figure 4B). Immunoblotting with an antibody
cocktail that recognizes components of the mitochondrial respi-
ratory chain/ATP synthase indicated that AMPD1 deletion did
not induce changes in mitochondrial biogenesis either in EDL
or soleus (Figure 3E).s and AMP-Activated Protein Kinase Signaling in Contracting Rat
hicle control or 27 mMcompound 3 (cpd 3) for 60min prior to 10min of electrical
n under resting conditions.
acts by HPLC (see Experimental Procedures) and expressed as n mol.g of wet
P), and (J), total adenine nucleotides (ATP + ADP + AMP) were calculated.
n of AMPK and ACC phosphorylation as the ratios of band intensities obtained
ntibodies, n = 8.
l ACC, phospho-AMPK, and total AMPK antibodies as indicated.
ce (p < 0.05), see also Figure S1.
0, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1501
Figure 2. Effect of Compound 4 on Purine Nucleotide Concentrations and AMP-Activated Protein Kinase Signaling in Contracting Rat Epi-
trochlearis Muscle
Muscles were incubated with or without 27 mM compound 4 (cpd 4) for 60 min prior to electrical stimulation as described in the legend to Figure 1.
(legend continued on next page)
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Figure 3. AMP Deaminase and AMP-Acti-
vated Protein Kinase Activities in Incubated
Extensor Digitorum Longus and Soleus
Muscles from Ampd1 Knockout versus
Wild-Type Mice Subjected to Electrical
Stimulation
Incubated EDL and soleus muscles from wild-type
and Ampd1 KO mice were electrically stimulated
for 5 min with 100 Hz trains of 200 ms duration
delivered every 2 s (EDL) and 125 Hz trains of
300 ms duration delivered every 1 s (soleus), or
incubated for 5 min under resting conditions.
(A–D) Homogenates were prepared from EDL (A
and B) or soleus (C and D) for AMPD and AMPK
assay. Extracts were immunoprecipitated with
anti-a1-AMPK plus anti-a2-AMPK antibodies prior
to AMPK assay. AMPK activity is expressed in
‘‘fold-change’’ relative to resting muscles. The
control AMPK activities were 6.3 ± 1.9 and 6.3 ±
1.2 mUnits/mg of protein for EDL and soleus,
respectively.
(E) Representative immunoblots show signals ob-
tained with anti-AMPD1, anti-AMPD2, anti-
AMPD3, anti-GAPDH, and an anti-total OXPHOS
antibody cocktail including mitochondrial respira-
tory chain NADH dehydrogenase complex I b
subcomplex 8 (CI-NDUFB8), succinate dehydro-
genase complex II subunit b (CII-SDHB), ubiquinol-
cytochrome c reductase complex III core protein 2
(CIII-UQCRC2); cytochrome c oxidase I complex
IV (CIV-MTCO1), and ATP synthase mitochondrial
F1 complex V (CV-ATP5A) as indicated.
The results are means and error bars represent
SEM, n = 67. *Indicates a significant difference
(p < 0.05), see also Figure S2.
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Ampd1 KO mice by ex vivo mechanical measurements. Iso-
lated EDL and soleus muscles were maximally stimulated to
obtain fused tetani. EDL and soleus muscles from wild-type
and Ampd1 KO mice developed similar maximal stress (Fig-(A–F) Total purine nucleotide concentrations are expressed as n mol.g of wet weight1, n = 4.
(G–J) ADP/ATP, AMP/ATP ratios (G and H), AEC (I), and total adenine nucleotides (J) were calculated (see l
(K and L), AMPK and ACC phosphorylation were quantified as described in the legend to Figure 1, n = 78
(M) Representative immunoblots show signals obtained with phospho-ACC, total ACC, phospho-AMPK, an
Values are means and error bars represent SEM. *Indicates a significant difference (p < 0.05), see also Figu
Chemistry & Biology 21, 1497–1510, November 20, 2014ures 6A and 6B). We then investigated
the role of AMPD1 deletion during mus-
cle fatigue. A specific fatigue protocol
was applied to each muscle. Soleus
muscles were subjected to maximal
stimulation (125 Hz) trains of 300 ms
duration at 1 s intervals for 2 min,
whereas EDL muscles were stimulated
at 2 s intervals at 100 Hz to minimize
fast-twitch muscle susceptibility to fa-
tigue. While no change in force during
tetanus was seen in EDL (Figure 6C), so-
leus muscle from Ampd1 KO mice dis-
played significantly more force duringcontraction (Figure 6D). Although, there was no force devel-
oped by EDL between pulses of electrical stimulation (data
not shown), force developed in soleus during relaxation was
greater in muscles from Ampd1 KO compared with wild-type
mice (Figure 6E).egend to Figure 1).
.
d total AMPK antibodies as indicated.
re S1.
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Figure 4. Effect of AMP Deaminase1 Deletion on Purine Nucleotide Concentrations in Contracting Extensor Digitorum Longus Muscle
Incubated EDL muscles from wild-type and Ampd1 KO mice were electrically stimulated for 5 min with 100 Hz trains of 200 ms duration delivered every 2 s or
incubated for 5 min under resting conditions.
(A–G) Total purine nucleotide concentrations are expressed as n mol.mg of protein1.
(H–K), ADP/ATP, AMP/ATP ratios (H and I), AEC (J), and total adenine nucleotides (K) were calculated (see legend to Figure 1).
The results are means and error bars represent SEM, n = 4. *Indicates a significant difference (p < 0.05), see also Table S1.
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We first characterized our model of electrically stimulated rat ep-
itrochlearis muscles by measuring purine nucleotide concentra-
tions in response to a graded increase in intensity of contraction1504 Chemistry & Biology 21, 1497–1510, November 20, 2014 ª2014(Table 1). The progressive rise in IMP levels and concomitant de-
creases in AMP as the frequency of electrical stimulation
increased indicates that flux through AMPD increases in parallel
with the intensity of muscle contraction. Under basal conditions,
flux through AMPD would be very low due to its high KM, relativeElsevier Ltd All rights reserved
Figure 5. Effect of AMP Deaminase1 Deletion on Purine Nucleotide Concentrations in Contracting Soleus Muscle
Incubated soleus muscles from wild-type and Ampd1 KOmice were electrically stimulated for 5 min with 125 Hz trains of 300 ms duration delivered every 1 s or
incubated for 5 min under resting conditions.
(A–G) Total purine nucleotide concentrations are expressed as n mol.mg of protein1.
(H–K) ADP/ATP, AMP/ATP ratios (H and I), AEC (J), and total adenine nucleotides (K) were calculated (see legend to Figure 1).
The results are means and error bars represent SEM, n = 4. *Indicates a significant difference (p < 0.05), see also Table S2.
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Inhibition of AMPD and Effects on AMPK Activationto free AMP concentrations, in line with its role to protect against
loss of total nucleotides. At the lowest frequency of electrical
stimulation used in Table 1, preincubation with compounds 3
and 4, two small molecule AMPD inhibitors, potentiated the in-Chemistry & Biology 21, 1497–151creases in total AMP levels and the AMP:ATP ratio induced by
contraction (Figures 1 and 2). Pretreatment with compound 4
was particularly effective in that AMP rose to higher levels of
300 nmol/g wet weight (Figure 1C), and there was a decrease0, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1505
Figure 6. Effect of AMP Deaminase1 Dele-
tion on Force Generation during Contraction
(A and B) Maximal tetanic stress (see Experimental
Procedures) was measured in EDL (A) and soleus
(B) muscles from wild-type and Ampd1 KO mice
(n = 67).
(C and D) Force was measured during the fatigue
protocol in EDL (C) and soleus (D) and quantified as
maximal force produced every 10 s.
(E) Force was also measured between the pulses
of electrical stimulation in soleus muscles from
wild-type and Ampd1 KO mice.
The results are expressed as the percentage of the
first tetanus. The results are means and error bars
represent SEM. *Indicates p < 0.05 (by one-way
ANOVA, repeated-measurements, n = 67).
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compounds 3 and 4 potentiated AMPK activation as well as ACC
phosphorylation by contraction (Figures 1 and 2), but failed to
improve contraction-stimulated glucose uptake (Figure S1).
This might be explained by the differential activation of hetero-
trimers by contraction and compound treatment. Indeed, activa-
tion of a2b2g3 AMPK seems to be involved in muscle glucose
uptake during exercise, while a2b2g1 AMPK represents most
(80%) of the AMPK present in human muscle (Birk and Wojtas-
zewski, 2006; Treebak et al., 2007). Also, AMPK activation is
probably not the only mechanism by which contraction stimu-
lates glucose uptake into muscle. Indeed, glucose uptake was
unaltered in EDL and soleus from a2- or a1-AMPK KOmice sub-
mitted to electrical stimulation (Jørgensen et al., 2004), while
glucose uptake was impaired in the b1b2 double KO in skeletal
muscle (O’Neill et al., 2011). Also, contraction-stimulated
glucose transport in tibialis anterior and in EDL and in gastrocne-
mius fromAMPKa2-inactivemice in vivo was normal, suggesting
regulation by a redundant mechanism in which a2-AMPK is but
one of multiple signaling pathways (Fujii et al., 2005).1506 Chemistry & Biology 21, 1497–1510, November 20, 2014 ª2014 Elsevier Ltd All rights rWe investigated effects of electrical
stimulation on AMPK activation and pu-
rine nucleotide concentrations in EDL
and soleus muscles from Ampd1 KO
mice. Contraction-induced AMPK activa-
tion in EDLmuscles from Ampd1 KOmice
was not potentiated (Figure 3), despite
dramatic changes in adenine nucleotides
(7-fold increase in AMP and 2.5-fold in-
crease in ADP). IMP production during
contraction was almost totally abrogated
in EDL muscles from Ampd1 KO mice,
confirming loss of AMPD1. On the other
hand, AMPK activation was significantly
potentiated in soleus muscles from
Ampd1 KO mice, but only from 2- to 3-
fold. Again, the rise in IMP observed in
wild-type soleus muscles induced by
contraction was reduced in soleus, but
the decrease in IMP was less marked
than in EDL from Ampd1 KO mice. This
might have been due to AMPD2 andAMPD3 expression in soleus (Figure 3E). However, the lack of
potentiation of AMPK activation by contraction in EDL and the
small increase in AMPK activation by electrical stimulation in so-
leus are very surprising faced with the huge fold-increases in
AMP levels in muscles from Ampd1 KO mice (Figures 4C and
5C). That the rise was indeed in AMP was confirmed by enzy-
matic measurement of AMP in perchlorate extracts and by
tandem mass spectrometry (data not shown). In EDL muscles
incubated with electrical stimulation for 15 min, beyond 5 min
used in Figure 3, AMPK activation increased from about 2- to
about 4-fold (Figure S2), clearly showing that AMPK activation
had not ‘‘maxed out’’, and that total AMPK activity could be
increased further with longer exposure to contraction. The re-
sults could be explained if, upon contraction of muscles from
Ampd1 KO mice, AMP, and AMPK are in different compart-
ments, or if the rise in AMP would not be sufficient to produce
an increase in free AMP concentration that would be required
to activate AMPK. Also, the contraction-induced increase in
IMP might be needed for AMPK activation by upstream kinase
or to protect against Thr172 dephosphorylation. In contractingeserved
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2 nmol/mg of protein (Figure 5C). We estimate that 1 g of wet
weight of muscle (rat epitrochlearis) contains 80 mg of protein.
On this basis, total AMP would rise to160 nmol/g in electrically
stimulated soleus fromAmpd1KOmice comparedwith values of
150 nmol/g and 300 nmol/g in contracting epitrochlearis
muscles treated with compound 3 (Figure 1C) and compound
4 (Figure 2C), respectively. In electrically stimulated rat soleus
muscles, total AMP levels were reported to rise from 50 nmol/g
to 130 nmol/g, which led to a10-fold increase in AMPK activity
(Ihlemann et al., 2000). Therefore, in the different models, the
total AMP concentrations seen during contraction are quite
similar. Free AMP concentrations are very low due to binding
to intracellular proteins, mainly fructose-1,6-bisphosphatase
and glycogen phosphorylase (Halfman and Marcus, 1982; Ren
and Hultman, 1990). In rat gastrocnemius electrically stimulated
for 30 min, a 4-fold increase in AMPK activity was associated
with a rise in total AMP from 65 (rest) to 90 nmol/g (30 min stim-
ulated), and a calculated rise in free AMP from 0.16 (rest) to
1.86 nmol/g (10 min stimulated) (Hutber et al., 1997). Therefore,
deletion of AMPD1 leading to dramatic potentiation of the rises in
AMP levels during contraction (Figures 4C and 5C) should have
greatly enhanced AMPK activation, which was not the case (Fig-
ure 3). Our results support the suggestion that in addition to
AMP, there could be another hitherto unidentified metabolite,
which would control AMPK activation (Xiao et al., 2013). Other
AMP-sensitive enzymes are glycogen phosphorylase and 6-
phosphofructo-1-kinase. However, measurements of glycogen
content and lactate concentration suggest that glycogen break-
down and glycolysis were not enhanced by contraction in mus-
cles from Ampd1 KO compared with wild-type mice (Tables S1
and S2).
In human AMPD1 deficiency, the most common metabolic
muscle disorder, individuals display symptoms of exercise intol-
erance (Teijeira et al., 2009), but whether basal AMPK activities
are affected is unknown. Here in soleus muscles, AMPD1 dele-
tion led to a potentiation of AMPK activation by contraction (Fig-
ure 3D). Also, AMPD1 deletion in soleus resulted in significantly
increased force development (Figure 6D) and more force be-
tween pulses of electrical stimulation (Figure 6E). However, in
Lkb1 KO mice where AMPK activation is lost, diaphragm mus-
cles were reported to fatigue more quickly (Brown et al., 2011).
We performed treadmill running experiments on wild-type
versus Ampd1 KO mice, but the results were inconclusive
(data not shown). Basically, while most Ampd1 KO mice did
run longer, the observation was not consistent either in female
or male animals. It remains to be seen whether AMPK activation
could increase contractility in skeletal muscle, as observed in the
heart (Oliveira et al., 2012).
In conclusion, compounds 3 and 4 are clearly not exercise mi-
metics, since basal AMPK activity was unaffected by the com-
pounds. Under resting conditions AMPD flux in muscle would
be low, and the high KM of AMPD would limit the loss of en-
ergy-costly purines. During energy stress, AMPD flux increases,
and under these conditions compounds 3 and 4 were able to
potentiate contraction-induced AMPK activation, but without
resulting in a stimulation of glucose transport. However, since
the increase in ACC phosphorylation due to electrical stimula-
tion was also potentiated (Figures 1M and 2M), one wouldChemistry & Biology 21, 1497–151expect fatty acid oxidation to be enhanced by the compounds.
Compounds 3 and 4 could thus be useful tools for studying ef-
fects of AMPK activation in vitro in cells and tissues other than
muscle.
SIGNIFICANCE
A large proportion of circulating glucose is taken up by skel-
etal muscle, where AMPK activation during exercise in-
creases glucose transport, considered to be beneficial in
humans for the management of type 2 diabetes. Therefore,
we focused on the consequences of AMPD inhibition for
AMPK activation by contraction in this tissue. Pharmacolog-
ical AMPD inhibition, aswell as AMPDdeletion inmice, led to
a substantial enhancement of contraction-induced AMP
accumulation in skeletal muscles. However, this did not
systematically lead to potentiation of AMPK activation in
response to electrical stimulation, suggesting that AMP
and AMPK might move to different compartments during
contraction, or that the rise in AMP would not be sufficient
to produce an increase in free AMP concentration needed
to activate AMPK. Also, pharmacological AMPD inhibition
did not enhance contraction-stimulated glucose uptake,
supporting the notion that pathways other than AMPK are
involved. Our findings support a role for AMPD in protecting
against loss of adenine nucleotides. Thus AMPD inhibitors
are not exercise mimetics, but would be useful tools to
modulate adenine nucleotide levels for exploring AMPKacti-
vation in muscle and perhaps in other tissues and cells sub-
jected to ATP-depletion.
EXPERIMENTAL PROCEDURES
Materials
Protease inhibitor cocktail tablets (Roche Diagnostics), glutamate dehydroge-
nase (Roche Diagnostics), and Protein G Sepharose (GE Healthcare) were
from the indicated sources. The AMARA peptide (AMARAASAAALRRR) for
AMPK assay was synthesized by V. Stroobant (Ludwig Institute for Cancer
Research, Brussels, Belgium). Phosphocellulose P81 paper (Whatman) and
[g-32P] ATP, D-[1-14C] mannitol, and 3-O-methyl-D-[1-3H] glucose were from
PerkinElmer. Anti-total a1- and a2-AMPK antibodies were kindly provided by
D.G. Hardie (University of Dundee, UK). Anti-eEF2 antibody was from Santa
Cruz. For secondary antibodies conjugated to peroxidase, anti-goat and
anti-mouse antibodies were from Santa Cruz, anti-rabbit antibody was from
GE Healthcare, and anti-sheep antibody was from Sigma. Anti-phospho-
AMPK Thr172 antibody was from Cell Signaling. Anti-ACC1 Ser79 (equivalent
to Ser218 in rat ACC2 and Ser211 in mouse ACC2) and anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibodies were from Millipore. Anti-
AMPD2 antibody was from Abnova. Anti-AMPD1, anti-AMPD3, and total
OXPHOS antibody cocktail were from Abcam. Lactate dehydrogenase, hexo-
kinase, glucose-6-phosphate dehydrogenase, and creatine phosphokinase
were from Roche. Solvents and acids for HPLC analysis were from Biosolve,
all other chemicals were from Sigma-Aldrich.
Generation of Ampd1 Deficient Mice
All experiments were approved by Gothenburg Ethics Committee for Experi-
mental Animals. A locus of X-over P1 (Lox-P) strategy was used to target the
AMPD locus in order to generate Ampd1 deficient mice. In essence, a 14.5 ki-
lobases C57BL/6 mouse genomic sub clone was used as targeting vector,
containing a floxed neomycin phosphotransferase selection marker cassette
after the coding sequence in the untranslated region, and a single Lox-P site
inserted in intron 6 of the AMPD locus (see Admyre et al., 2014 in this issue
of Chemistry & Biology).0, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1507
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All animal experiments were approved by the Animal Ethics Committee of the
Universite´ catholique de Louvain Medical Faculty. Muscle mechanical mea-
surements were performed as previously described (Zanou et al., 2010).
Briefly, 12- to 16-week-old wild-type and Ampd1 KO mice were anesthetized
by intraperitoneal injection of a solution containing ketamine (10 mg/kg) and
xylazine (1 mg/kg) to induce deep anesthesia and preserve muscle perfusion
during dissection of both EDL and soleus muscles. Muscles were bathed in a
1 ml horizontal chamber continuously perfused with HEPES-buffered Krebs-
Henseleit solution (100% O2) containing 135.5 mM NaCl, 5.9 mM KCl, 1 mM
MgCl2, 2.5 mM CaCl2, 11.6 mM HEPES, and 11.5 mM glucose buffered to
pH 7.4 with HCl and maintained at a temperature of 20 ± 0.1C. One end
of the muscle was tied to an isometric force transducer, and the other end
was attached to an electromagnetic motor and length transducer (Mare´chal
and Beckers-Bleukx, 1993). Electrical stimulation was applied via platinum
electrodes running parallel to the muscles. The resting muscle length (L0)
was carefully adjusted for maximal isometric force with 100 ms (EDL) or
300 ms (soleus) maximally fused tetani. Force was recorded on a high-speed
pen recorder (Sanborn model 320) and digitalized at a sampling rate of 1 kHz
with a peripheral component interconnect 6023E in/out card (National Instru-
ments). Normalized stress was expressed relative to cross-sectional area,
obtained by multiplying absolute force by the quotient muscle fiber length
(mm) per muscle blotted weight (mg), and considering the fiber length equal
to L0 for soleus and equal to 0.5 3 L0 for EDL (Brooks and Faulkner, 1988).
To investigate muscle fatigue, soleus muscles were subjected to 125 Hz
stimulation trains of 300 ms duration at 1 s intervals, and EDL muscles to
100 Hz stimulation trains of 200 ms duration at 2 s intervals both over 2, 5,
or 15 min.
Male Wistar rats (150 g body weight) were anaesthetized intraperitoneally
with sodium pentobarbital (50 mg/kg). Epitrochlearis muscles were rapidly
removed and mounted as described (Aslesen et al., 2001). The muscles
were preincubated with 0.1% (volume for volume [v/v]) DMSO as vehicle con-
trol or 27 mM compound 3 or compound 4 (free concentrations 20 mM) for
60 min in Krebs-Henseleit bicarbonate (KHB) buffer (120 mM NaCl, 4.7 mM
KCl, 1.25 mM MgSO4, 1.2 mM KH2PO4, 2.5 mM CaCl2, and 25 mM NaHCO3)
at pH 7.4 containing 5.5 mM glucose, 2 mM sodium pyruvate, and 0.1%
(weight for volume [w/v]) bovine serum albumin, followed by 10 min of incuba-
tion with or without contraction. Contraction was induced by electrical stimu-
lation with 200 ms trains delivered every 10, 5, and 1 s at 100 Hz as described
(Aslesen et al., 2001). After incubation, the muscles were blotted and frozen
rapidly in liquid N2.
Preparation of Muscle Extracts
Muscle extracts were prepared essentially as described (Lai et al., 2012).
Briefly, EDL and soleus muscles were homogenized (Ultra-Turrax fitted with
a T 10 disperser, 2 3 10 s) in 500 ml of ice-cold lysis buffer containing
50 mM HEPES pH 7.6, 0.1% (w/v) Triton X-100, 50 mM KF, 50 mM KCl,
5 mMNa4P2O7, 1 mMEDTA, 1mM EGTA, 5mM sodium b-glycerolphosphate,
protease inhibitor cocktail, 1 mM NaVO3, and 1 mM dithiothreitol. The homog-
enates were centrifuged (Eppendorf microfuge, full speed 3 10 min at 4C),
and the supernatants stored at 80C prior to enzyme assay and protein esti-
mation. For purine nucleotide measurements, 500 ml of ice-cold 0.1 M HClO4/
40% (v/v) CH3OH was added to frozen muscles, which were extracted with an
Ultra-Turrax as described above. After centrifugation (Eppendorf microfuge,
full speed 3 10 min at 4C), the supernatants were neutralized with 1.1 M
(NH4)2HPO4, evaporated to dryness, and resuspended in 100 ml of HPLC-
grade water for storage at 20C prior to analysis. The remaining cell pellets
were resuspended in 0.5 M NaOH for protein estimation. Otherwise, protein
concentrations in extracts were determined by the Bradford method using
bovine serum albumin as a standard.
Measurement of Glucose Transport in Incubated Rat Epitrochlearis
Muscle
Rat epitrochlearis muscles were preincubated for 60 min with or without
compound 3 or compound 4. The muscles were then incubated with and
without electrical stimulation (200 ms trains delivered every 5 s) for
10 min. Muscles were rapidly washed twice with prewarmed KHB buffer
and then incubated without glucose, but with addition of 1 mM 3-O-1508 Chemistry & Biology 21, 1497–1510, November 20, 2014 ª2014methyl-D-[1-3H] glucose (0.25 mCi/mmol) and 0.1 mCi/ml D-[1-14C] mannitol
for 10 min. The rate of glucose transport was calculated as the accumula-
tion of intracellular 3-O-methyl-D-[1-3H] glucose as described (Funai and
Cartee, 2009).
Enzyme Assays
AMPD was assayed spectrophotometrically in a final volume of 1 ml of 50 mM
HEPES pH 7.0, 100 mM KCl, 1 mM EDTA, 1 mM dithiothreitol, 5 mM a-keto-
glutarate, 0.15 mM nicotinamide adenine dinucleotide phosphate (reduced
form), and five units of glutamate dehydrogenase containing 0.15 mg of
extract protein by starting with 10 mM AMP and following the decrease in
absorbance at 340 nm at 37C (Chapman and Atkinson, 1973). One unit of
activity corresponds to the amount of enzyme catalyzing the formation of
1 mmol of product/min under the assay conditions. AMPK activity in extracts
(100 mg of muscle lysate protein) was measured after immunoprecipitation
with anti-a1 or anti-a2 antibodies (Woods et al., 1996) using the AMARA pep-
tide as substrate. Conditions were first established for optimal immunopre-
cipitation and linearity as a function of time and of protein concentration,
adapted from (Marsin et al., 2000; Mitchelhill et al., 1994). Briefly, immunopre-
cipitated AMPK was incubated at 30C in a final volume of 50 ml containing
20 mM 3-(N-morpholino)propanesulfonic acid pH7, 0.1 mM EDTA, 0.1%
(v/v) b-mercaptoethanol, 5 mM magnesium acetate, 1 mM dithiothreitol,
0.01% (w/v) Brij-35, 0.2 mM AMP, and 0.2 mM AMARA peptide. The reac-
tions were started with [g-32P] ATP (0.1 mM, specific radioactivity 1,000
cpm/pmol), and aliquots (5 ml) were taken after 10, 20, and 30 min of incuba-
tion for spotting onto P81 phosphocellulose paper to measure 32P-incorpora-
tion (Glass et al., 1978). One unit of AMPK activity corresponds to the amount
of enzyme catalyzing the formation of 1 nmol of product/min under the assay
conditions.
Immunoblotting
The indicated amounts of extract proteins were separated by SDS-PAGE in
7% (w/v) acrylamide gels or 4%–15% (w/v) acrylamide gradient gels and
transferred to polyvinylidene fluoride (PVDF) membranes by electroelution.
Blots were probed with the relevant primary antibodies, followed by horse-
radish peroxidase-coupled secondary antibody for the detection of immu-
noreactive bands by enhanced chemiluminescence. Band intensities were
quantified by scanning films and processing image intensities with the pro-
gram ImageJ (133 for Mac OS X). For skeletal muscles, equal amounts of
lysates (corresponding to about 30 mg of protein) were loaded into each well
of a 4%–15% polyacrylamide gradient gel (BioRad) for protein separation by
SDS-PAGE. Proteins were then transferred to PVDF membranes and for
immunodetection as described (Lai et al., 2012).
Purine Nucleotide Measurements
HPLC separation of purine nucleotides was carried out with an Agilent 1260
Infinity system (Agilent Technologies) with the multiple wavelength detector
set to measure absorbance at 248, 254, and 262 nm simultaneously. Samples
(10 ml) were injected via the auto-sampler, set at 4C, onto a reverse-phase col-
umn (Waters Atlantis T3 100 mm 3 3 mm ID, 3mm particles) equilibrated with
0.1M ammonium phosphate pH 6.0 (solvent A) at a flow rate of 300 ml/min. Nu-
cleotides were separated using the following gradient program: 0%–15% (v/v)
solvent B (50% [v/v] methanol in solvent A) from 2 to 10 min, 15%–50% (v/v)
solvent B from 10 to 18 min, and 50%–100% (v/v) solvent B from 18 to
19min. Quantification of nucleotides was by peak integration of the area under
the curve, verified using external standards of known concentration as deter-
mined by the molar extinction coefficient.
Statistical Analysis
Statistical analysis was performed using a Student’s unpaired two-sided t test
or by one-way ANOVA. In the figures, error bars represent SEM unless stated
otherwise.
Other Methods
Glycogen content, lactate, and PCr concentrations were measured as
described (Aslesen et al., 2001). Protein was estimated with g-globulin as a
standard.Elsevier Ltd All rights reserved
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